There is broad agreement that fibrosis often follows inflammation and that both associate with a decline of renal function in chronic kidney disease (CKD), but their causal relationship remains under debate. 1, 2 It is noteworthy that inflammation is a clinical term. Histologically, inflammatory lesions usually involve leukocyte recruitment. However, the presence of leukocytes in renal biopsies must not necessarily indicate inflammation. This distinction has become important because leukocytes with anti-inflammatory or profibrotic phenotypes are increasingly recognized like regulatory T cells, fibrocytes, alternatively activated macrophages, or myeloid-derived suppressor cells (MDSCs). 3 The ongoing debate to what extent interstitial fibrosis on its own just accompanies or actively promotes progressive CKD will benefit from considering inflammatory tissue damage, insufficient epithelial healing, and mesenchymal healing as separate pathophysiological entities that altogether make up the histopathological abnormalities in CKD. In this review, we discuss the evolving evidence on the impact of distinct macrophage phenotypes on 'inflammation', 'epithelial healing' , 'mesenchymal healing' , and the 'resolution of fibrosis'. Along the discussion, we learn how these distinct and evolutionary conserved danger defense programs involve the differentiation of recruited monocyte into different tissue macrophage phenotypes that amplify their surrounding tissue environment, a process that often leads to end-stage renal disease, although intended to maintain tissue homeostasis.
Healing of tissue damage is as ancient as the evolution of the metazoa. 4 In primitive organisms, healing is mostly complete without scarring, because of the high regeneratory capacity of epithelia from their progenitor cells. This functional property is limited in complex tissues of higher organisms including the skin, although rapid and scarless healing is partially maintained at embryonic and fetal stages of development. 5, 6 Healing of mammalian skin wounds is often taken as a general model to describe the serial danger response programs that are involved in the healing process (Table 1) ; that is, (1) clotting to avoid fatal blood loss, (2) inflammation and (3) reepithelialization to avoid fatal sepsis, (4) fibrosis to limit wound surface and to endure the injured tissue, and (5) resolution of the fibrous matrix resulting in the smallest possible scar area necessary. 6, 7 Macrophages contribute to stages 2-5 of the wound healing process (Table 2) , 8 and we need to anticipate that their functional heterogeneity is the result of different tissue environments at each of these stages. At the early inflammatory stage, proinflammatory macrophages produce multiple cytokine-, lipid-, and oxygen-derived mediators that support neutrophils in direct pathogen killing (for example, by the release of reactive oxygen species), and indirectly by activating the tissue's innate host defense (cytokine release) and by recruiting additional immune cells (chemokine release). Although inflammation protects from sepsis, its related mediators limit the capacity for epithelial healing as documented by an accelerated reepithelialization of sterile wounds in PU.1-deficient mice that lack neutrophils and macrophages, or in MyD88-deficient mice that largely lack innate immune responses. [9] [10] [11] This is because the killing effect of reactive oxygen species or tumor necrosis factor (TNF) is not only limited to pathogens but also promotes cell cycle arrest or apoptosis in epithelial and endothelial cells. 12 In chronic wounds, macrophage iron overloading maintains the proinflammatory macrophage phenotype that continues to damage tissue cells. 13 Interestingly, this process promotes fibroblast senescence rather than proliferation, arguing against the concept that inflammation per se is a driver of fibrogenesis. In fact, chronic (leg) ulcers, such as those in pyoderma grangraenosum, are associated with loss of tissue rather than with excessive fibrosis. In contrast, when inflammation is only transient, such as in acute and sterile wounds, clearing apoptotic neutrophils induce macrophages that have the potential to suppress the inflammatory response together with other immunosuppressive lymphocytes. 8 To reiterate this point, leukocytes in injured tissues must, therefore, not necessarily indicate ongoing 'inflammation'. In addition, profibrotic macrophages promote fibroblast proliferation and fibrogenesis in the fourth stage of wound healing because they secrete large amounts of tumor growth factor-b (TGF-b) and other profibrotic cytokines. At the resolution stage, macrophages promote the clearance of unnecessary extracellular matrix (ECM), referred to as fibrolysis. Thus, from the perspective of wound healing, at least four different types of macrophages with predominant functional phenotypes should exist: proinflammatory macrophages, anti-inflammatory macrophages, profibrotic macrophages, and fibrolytic macrophages (Figure 1 ).
CLASSIFYING MACROPHAGE PHENOTYPES
How can we identify different macrophage phenotypes? The functional heterogeneity of tubular epithelial cells is evident by their unique structural appearance on light microscopy. Phenotypic changes of podocytes require electron microscopy to image their structural rearrangement. In contrast, the phenotypes of leukocytes can only reliably be characterized by functional assays such as cytokine release profiles or by assessing their surface marker expression by flow cytometry. For example, these two methodological approaches have enormously expanded our knowledge about T-cell subtypes and how these promote different outcomes of kidney disease. 14, 15 Similarly, functional assays and flow cytometry are now increasingly used to unravel the functional contribution of heterogeneous macrophage populations. 16, 17 For example, distinct surface markers allow to distinguish circulating monocyte populations, as well as different tissue macrophage phenotypes, although different markers must be considered when studying mouse or human macrophages (Table 2) . A detailed discussion of classifying macrophages by their surface marker expression profiles has been provided elsewhere. 18 An unsolved problem, however, is the inconsistency between in vitro macrophage studies and the heterogeneity of tissue macrophages in vivo, which relates to their phenotype plasticity in complex microenvironments. 17 For example, in vitro studies have dissected classically activated M1 macrophages and alternatively activated M2a, M2b, and M2c macrophages according to their phenotypes upon stimulation with defined stimuli. 16, 17, 19 This working model raised a lot of interest on macrophage heterogeneity, but it has become clear that complex tissue environments are not adequately mirrored by the M1/M2 paradigm. In the following, we intend to refine the M1/M2 macrophageworking model in view of the aforementioned putative macrophage phenotypes that occur during the different phases of wound healing, and we will discuss how they might contribute to renal inflammation and fibrosis.
PROINFLAMMATORY MACROPHAGES
Acute tissue injury triggers a rapid influx of neutrophils that is soon followed by an increased adhesion of circulating monocytes to activated endothelial surfaces and their subsequent extravasation into interstitial compartments. 20 At sites of acute tissue injuries, the interstitial microenvironment is dominated by danger signals released from necrotic cells (damage-associated molecular patterns (DAMPs)), such as HMGB1, ATP, uric acid, or hypomethylated DNA. 21, 22 Erythrocyte-derived iron serves as an important DAMP in skin wounds. 13 External surfaces of the skin, gut, or the respiratory tract are exposed to pathogens that release pathogen-associated molecular patterns (PAMPs) that have an identical potential to activate Toll-like and other innate pattern recognition receptors on leukocytes and parenchymal cells of the affected tissue ( Figure 1 ). The same immunostimulatory responses occurs inside the kidney, although a PAMP contribution is less frequent. 21, 23, 24 Toll-like receptor (TLR) activation of the transmigrated monocyte requires interferon-related factor (IRF)5 for full activation of NF-kB signaling and the secretion of proinflammatory cytokines/ chemokines, reactive oxygen species, and other proinflammatory mediators that define a proinflammatory macrophage phenotype (Figure 2) . 25 Interferon-g, secreted by Th1 T cells and natural killer cells, or granulocyte-macrophage colony-stimulating factor, are major components of the cytokine microenvironment and further promote this inflammatory tissue macrophage phenotype, as documented for lupus nephritis, allograft rejection, or crescentic glomerulonephritis. [26] [27] [28] Proinflammatory macrophages release matrix metalloproteases (MMPs) to enable their migration through basement membranes and interstitial ECM networks, but the resulting small ECM peptides themselves can function as immunostimulatory DAMPs via TLRs and maintain the proinflammatory macrophage phenotype. 29 The secretory profile of inflammatory macrophages mirrors to what has been classified as an 'M1' macrophage by in vitro stimulation with lipopolysaccharide and other microbial products (Table 3) . 19 It is intriguing to speculate that the predominance of this bactericidal macrophage phenotype in early phases of tissue injury has been positively selected throughout evolution for host defense against pathogens, an important and potentially life-saving danger response element that outweighs the collateral tissue damage that occurs because of the unspecific toxicity of the secreted mediators. However, the sterile kidney mostly suffers from proinflammatory macrophages infiltrates. For example, proinflammatory macrophages release large amounts of TNF, 
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Kidney International (2011) 80, 915-925 a cytokine with two major biological functions. First, TNF has an autocrine/paracrine effect on macrophage activation. Second, the proapoptotic effects of TNF limit the survival of activated immune cells 30 but, as a side-effect, also induces activation and apoptosis of renal parenchymal cells such as vascular endothelial cells, tubular epithelial cells, and podocytes that all express TNF receptors. [31] [32] [33] [34] As such, extra/ intrarenal infections or renal cell necrosis in AKI create a DAMP(PAMP)-rich intrarenal microenvironment that promotes differentiation of arriving monocytes toward the proinflammatory phenotype, further amplifying intrarenal inflammation and loss of renal parenchymal cells, for example in anti-GBM glomerulonephritis, 35 lupus nephritis, [36] [37] [38] [39] [40] [41] antigen-induced immune complex glomerulonephritis, 42 renal allograft injury, 43 ischemia-reperfusion injury, [44] [45] [46] and adriamycin nephropathy. Once inflammation has ceased, the microenvironment is dominated by growth factors that promote wound healing, especially in conditions of incomplete or insufficient epithelial repair. This environment drives macrophage polarization toward a profibrotic phenotype that contributes to growth factor secretion. Theoretically, the ischemic environment of a fibrotic kidney is largely devoid of cytokines and growth factors, and it will be important to study whether fibrolytic macrophages that have the potential to remove connective tissue from the kidney exist. It is important to note that all four categories are arbitrary, and that in vivo mixture variants in a patchy distribution will determine non-homogenous histopathological lesions in chronic kidney disease. This needs to be considered when attempting to characterize macrophage phenotypes from renal biopsies. Although clodronate liposome-or diphtheria toxinmediated macrophage ablation studies do not allow to conclude on the functional contributions of only proinflammatory macrophages, some interventions are rather specific for this macrophage phenotype. 48, 49 For example, Met-Rantes and AOP-Rantes, two mutant chemokines, rather reduced glomerular macrophage numbers but activated those macrophages that reached the glomerulus, which was sufficient to aggravate antigen-induced glomerulonephritis. 50 In addition, activated monocytes express the chemokine receptor CCR2, which mediates their recruitment to sites of monocyte chemoattractant protein-1/chemokine ligand (CCL) 2 expression. 19, 51 Blockade of either monocyte chemoattractant protein-1/ chemokine ligand 2 or CCR2 substantially reduces the number of proinflammatory macrophages in inflamed tissues, an effect that was shown to reduce immunopathology in a large number of inflammatory kidney disease models. 52, 53 Furthermore, renal ischemia-reperfusion models allow to distinguish the phases of renal damage and repair. A recent study clearly demonstrated that the early influx of proinflammatory M1 macrophages largely determine acute kidney injury, for example, by early clodronate depletion of macrophages and transfer of ex vivo primed M1 macrophages. 46 It has been proposed that proinflammatory macrophages directly promote renal fibrosis, 54 but DAMP/PAMP exposure does not activate macrophages (nor even fibroblasts) to secrete profibrotic cytokines such as TGF-b1 (H-J Anders and M Ryu, unpublished data). In addition, non-inflammatory models of renal fibrosis, such as Alport nephropathy, do not benefit from monocyte chemoattractant protein-1/chemokine ligand 2 blockade, indicating that proinflammatory macrophages are of minor importance in certain types of renal fibrosis. 55 Furthermore, and as mentioned before, proinflammatory macrophages rather induce fibroblast senescence. 13 Together, infectious organisms and/or cell necrosis release PAMPs and DAMPs that create a distinct tissue microenvironment that activates infiltrating monocytes via TLRs and other innate pattern recognition receptors towards a proinflammatory phenotype. Enhanced pathogen killing causes collateral tissue damage, for example, via release of reactive oxygen species, MMPs, and proapoptotic cytokines. Proinflammatory macrophages rather suppress epithelial repair or fibroblast proliferation. As a consequence, reducing activated proinflammatory macrophages can prevent immunopathology in injured kidneys.
ANTI-INFLAMMATORY MACROPHAGES
Many types of kidney diseases are devoid of infection or renal cell necrosis, and the intrarenal microenvironment will rather be dominated by renal cell apoptosis. Apoptotic cell death is fundamentally different from necrotic cell death because apoptosis (but not necrosis) is a central element of homeostasis. 56 Phagocytic clearance of apoptotic cells by macrophages is an important physiological element of tissue homeostasis and immune tolerance; hence, it is not associated with immune activation and rather stimulates epithelial healing. 57, 58 In fact, apoptosis of activated neutrophils and T cells is a mechanism that prevents inappropriate or persistent immunopathology. When apoptosis occurs in the context of infection, coexposure of TLR agonists and apoptotic cells adds onto macrophage activation in an M1-like manner; however, this effect is short-lived and turns into sustained TGF-b release. 59 When pathogens or necrotic cell debris have been removed from tissues, the uptake of apoptotic cells gradually promotes rather an anti-inflammatory macrophage phenotype (Figure 1 ), as such macrophage infiltration in acute kidney injury has been considered as a 'clean-up crew' for apoptotic neutrophils. 45 Serum amyloid-P, also named pentraxin-2, opsonizes apoptotic cells, which further promotes the anti-inflammatory macrophage phenotype. 60 Interestingly, this process must not necessarily involve a signal for renal fibrosis; in fact, deactivating macrophages with pentraxin-2 has rather antifibrotic effects on the kidney. 60, 61 Immunosuppressive ('regulatory') T cells further promote the polarization towards anti-inflammatory macrophages via release of IL-10 and TGF-b. 62 It is of note that TGF-b has potent immunosuppressive effects and should, therefore, not exclusively be taken as a profibrotic cytokine. 63 An integration of these different environmental signals for the deactivation of the macrophage occurs at the level of the transcription factor IRF4, which also functions as an intracellular competitor of IRF5, and thereby blocks TLR and IL-1R signaling (Figure 2) . [64] [65] [66] [67] Evidence for a functional role of anti-inflammatory macrophages for renal healing responses comes from acute kidney injury studies using the acute ischemia-reperfusion model. In the postischemic kidney, M1 macrophages subsequently undergo a phenotypic switch toward anti-inflammatory M2 macrophages that promote tubular repair, a process driven by tubular epithelial cell-derived factors, as well as by the uptake of apoptotic neutrophils. 46 ,68 Lack of IRF4 enables 65 and therefore the aggravated postischemic inflammation induces acute tubular necrosis (without any evidence for renal fibrosis). 32 In addition, direct IL-4/IL-10 treatment or genetically modified or transfused IL-10-stimulated macrophages is able to resolve renal inflammation and injury. [69] [70] [71] [72] [73] Steroid-based treatments seem to suppress renal inflammation by inducing anti-inflammatory macrophages. 74 Hence, a macrophage phenotype that counteracts renal inflammation promotes epithelial healing and preserves renal function, 75 a process that regulates the balance of renal inflammation and (tubular) epithelial healing, and not necessarily fibrogenesis, in a direct way.
Macrophage classifications that are based on in vitro studies have not yet integrated apoptotic cells as a stimulus of differentiation, but the phenotype of cultured macrophages stimulated with IL-10 and TGF-b (or glucocorticoids), referred to as the M2c type, shares similarities with antiinflammatory macrophages (Table 3) . 19, [70] [71] [72] [73] 76, 77 These cells themselves produce large amounts of IL-10 that should mimic the in vivo situation and mirror the resolution of inflammation. 17 A conceptual proof for this concept was provided by Wang et al., 72 who observed an attenuation of adriamycin-induced renal pathology upon injection of M2 macrophages that had been primed ex vivo with IL-4 and IL-13. This aspect is shared by a group of tumor-associated macrophages that mediate immunosuppression in tumor environments. [78] [79] [80] In addition, MDSCs produce immune suppressive factors such as arginase I or inducible nitric oxidase synthase. The phenotype of MDSCs has been identified as CD11b þ Gr1 þ in mice, and as LIN-HLA-DR-CD33 þ or CD11b þ CD14ÀCD33 þ in humans. MDSCs can be distinguished from tumor-associated macrophages by the high expression of Gr-1 and low expression of F4/80. 3 Together, a microenvironment dominated by cell apoptosis and anti-inflammatory cytokines can deactivate proinflammatory macrophages or directly promote the differentiation into anti-inflammatory macrophages. It is noteworthy that anti-inflammatory macrophages amplify their anti-inflammatory environment in the same way as M1 macrophages amplify inflammatory environments. As such, anti-inflammatory macrophages abate many toxic and proapoptotic factors that limit efficient epithelial healing. Therefore, if inflammation is only short-term and transient, as in mild to moderate toxic or ischemia-reperfusion injury of the kidney, anti-inflammatory macrophages will enhance tubular reepithelialization. This process, if not hampered by persistent or recurrent injuries, can regenerate, for example, tubular structure and function, without significant interstitial fibrosis.
PROFIBROTIC MACROPHAGES/FIBROCYTES
Macrophage depletion almost always reduced interstitial fibrosis, and therefore it is concluded that macrophages are profibrotic. 1, 2, 54, 81 Given macrophage heterogeneity, it is now getting clear that anti-inflammatory macrophages do not necessarily trigger fibrogenesis directly, and that proinflammatory macrophages rather promote renal cell death. In view of the wound healing concept, inflammation and epithelial healing are primary danger response programs. In contrast, fibrosis is rather a second-line danger response program that only becomes relevant when epithelial healing is insufficient, incomplete, or persistently suppressed by ongoing injury and inflammation. 6, 7 In fact, epithelial cells and non-inflammatory (and not proinflammatory) macrophages are major sources of profibrotic cytokines that drive fibroblast growth. 82 Although platelet-derived growth factors (such as PDGF) and certain proinflammatory cytokines, such as IL-6, promote regenerative growth from the earliest stages of tissue damage, the renal microenvironment becomes dominated by growth factors released from damaged epithelia only with some delay (Figure 1) . 83 In vitro cytokines such as IL-4 and IL-13, for example, released from basophils and Th2 T cells, further promote a macrophage phenotype that predominantly releases fibronectin and other ECM molecules. 19 These cells have been classified as M2a macrophages (Table 3) . To what extent, or if at all, anti-inflammatory and profibrotic macrophages can be clearly distinguished in vivo remains unclear, and it appears likely that macrophage plasticity creates a mixture or continuous variant shifts in CKD lesions. The balance of these different M2 macrophages and their contribution to renal fibrosis deserves further study. However, ex vivo IL-4/IL-13-primed and injected macrophages displayed a stable phenotype in adriamycin-induced fibrosis. 72 Nevertheless, M2 macrophages predominate in fibrotic lesions, and it is intriguing to speculate that paradigmatic fibrotic kidney diseases such as Alport syndrome, Orellanus syndrome, Balkan nephropathy, Chinese herb nephropathy, or chronic allograft failure are associated with this profibrotic macrophage phenotype (Figure 3 ). First evidence comes from a study using collagen 4A3-deficient mice with Alport syndrome. Progression of Alport syndrome in these mice is associated with significant M2 macrophage infiltrates. 31 As such, blocking the monocyte chemoattractant protein-1/ CCR2 axis, an intervention that ameliorated many other murine CKD models, 84 was ineffective in Alport mice because only proinflammatory, but not anti-inflammatory or profibrotic (M2), macrophages express CCR2 (ref. 55) . In contrast, blocking the chemokine receptor CCR1, which is present on M2 macrophages, reduced interstitial macrophages and fibrosis and prolonged survival of collagen 4A3-deficient mice. 85 The profibrotic role of CCR1 þ interstitial macrophages was also confirmed in diabetic nephropathy of db/db mice, adriamycin-induced nephropathy, and after unilateral ureteral obstruction. [86] [87] [88] [89] However, CCR1 may not be selectively expressed by M2 macrophages; therefore, additional work is necessary to dissect the functional significance of this cell type. In contrast, mice deficient for the chemokine receptor CCR5 cannot activate macrophages through proinflammatory chemokines such as CCL3-5, CCL8, and CCL14. These mice are not generally protected from renal inflammation; 90 however, when wild-type kidneys are transplanted into Ccr5-deficient mice, the allograft developed a profound interstitial fibrosis associated with infiltrates of host M2 macrophages. 91 Fibrocytes have been described as another profibrotic myeloid cell type that shares phenotypic characteristics between monocyte/macrophages and fibroblasts. 92 Fibrocytes are fibroblast-committed monocytes that can be distinguished in the intravascular compartment from monocytes. [92] [93] [94] Some authors demonstrated that fibrocytes actively produce collagens once they enter sites of kidney injury, conceptually similar to a bone marrow-derived fibroblast progenitor cell. 95, 96 The quantitative significance of this phenomenon remains under debate. For example, green fluorescence protein lineage tracing using the collagen 1a1 promoter found this to be a rather rare phenomenon during renal fibrogenesis upon ureter obstruction in mice. 97 Together, renal fibrosis may not be directly triggered by proinflammatory macrophages but rather indirectly by (inflammation-mediated) insufficient epithelial healing or by profibrotic ('M2') macrophages and fibrocytes.
FIBROLYTIC MACROPHAGES
The evidence in the field of renal fibrosis is dominated by the broad use of the irreversible unilateral ureteral obstruction model, which is progressive in nature and does not allow studying a potential resolution of interstitial fibrosis. However, understanding the mechanisms of reversible fibrosis may offer novel perspectives for progressive CKD. It is important to note that fibrosis is potentially reversible, for example, in the last stage of dermal wound healing or after toxic liver injury. For example, the proper reconstruction of the epithelial compartment induces an orchestrated fibrolytic program that has the potential to an almost complete reversal of advanced interstitial fibrosis. 98 Macrophage depletion in the late phase of toxic liver fibrosis delayed the clearance of liver scars, 99 a process associated with MMP13 release by scar-associated macrophages. 100 Principally, the same fibrolytic program should operate in fibrotic kidneys. 101 Evidence for this concept comes from reversible glomerulosclerosis of patients with type I diabetes undergoing pancreas trans- plantation. 102 Experimental and clinical studies document the same for non-diabetic glomerulosclerosis treated for prolonged periods with angiotensin conversion enzyme inhibition. 103, 104 In addition, Zeisberg and Kalluri reported in a series of studies that recombinant human BMP7 is capable of regenerating severely abnormal kidney structures, including the disappearance of robust renal fibrosis. 105 Macrophages are capable of digesting such ECM deposits by the secretion of selected MMPs. 101 MMPs have the potential to limit or reverse fibrogenesis. 106 It is therefore intriguing to speculate that a macrophage subtype with predominant fibrolytic activity exists in the ischemic environment of scar tissue, which has the potential to digest ECM without concomitant secretion of proinflammatory cytokines (Figure 1 ). Surface markers that would allow to identify fibrolytic macrophages have not yet been described, but it should be technically feasible to isolate macrophages from non-inflammatory scarred skin or kidneys to characterize their phenotypic characteristics. Although the fibrolytic macrophage might be a rare guest inside the kidney, it would be instrumental to learn more about its potential to limit or to reduce renal fibrosis. It will be important to study whether increased clearance of ECM from the renal interstitium is of any functional benefit for renal function or rather results in tissue disintegration or in even faster shrinking kidneys. It has also become clear that MMP-secreting macrophages can also contribute to renal damage by degrading glomerular and tubular basement membranes and subsequent epithelial atrophy. 101, 107 Therefore, fibrolytic macrophages could also be basement membrane-degrading macrophages that rather contribute to renal atrophy. In fibrotic livers, however, transfer of bone marrowderived macrophages was shown to reverse hepatic fibrosis and improve regeneration and function of the liver. 108 
FUTURE PERSPECTIVE AND DIRECTIONS FOR RESEARCH
It is now becoming clear that macrophages contribute to renal pathology through functionally distinct phenotypes as recently discovered for dendritic cells, B cells or T cells (Figure 2) . A deeper knowledge about their temporal or spatial distribution in the kidney will certainly affect our understanding of renal immunopathology like it changed upon the discovery of Th1, Th2, Th17, and regulatory T cells. 15 However, to assess macrophage phenotypes is not yet as easy as with T cells. We are still in need of better surface markers that allow a convenient and distinctive identification of either phenotype by immunostaining or fluorescence-activated cell sorting. Such lineage-specific markers are needed to characterize the temporal appearance of each phenotype in the different phases of a single disease, as well as a comparison between different diseases (Figure 3 ). Gene profiling is another approach to determine the predominant macrophages, but it will always represent only pooled kidney data. 31, 91 So far, expression studies teach us that different macrophage subtypes coexist in CKD. Determining the predominant macrophage phenotype may be of prognostic value in terms of renal cell loss or fibrosis, or might allow to choose either an anti-inflammatory or an antifibrotic type of therapy. Lineage-specific markers will also guide the development of lineage-specific therapeutic tools. A selective neutralization of distinct macrophage phenotypes is ultimately necessary to determine the functional role of each macrophage type for kidney pathology. Although the current evidence suggests that preventing early renal inflammation by neutralizing proinflammatory macrophages is sufficient to prevent renal atrophy and fibrosis, we must admit that this may not apply to the treatment of non-inflammatory types of renal fibrosis or late stages of kidney diseases where other macrophage phenotypes predominate. Late-stage kidney disease might benefit from fibrolytic macrophages and hence we would like to motivate the renal community to start efforts to identify and characterize renal fibrolytic macrophages. This is attractive from a scientific point of view, although it remains controversial whether enhanced clearance of ECM from fibrotic kidneys without restoring renal parenchymal cells can have any beneficial impact on renal excretory function.
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SUMMARY AND CONCLUSIONS
Renal pathology is the result of different danger response programs that evolutionally derive from host defense and tissue repair upon injury. The sequence of danger response programs that occur after skin injury (inflammation-epithelial healing-mesenchymal healing-fibrolysis) has been positively selected throughout the evolution of multicellular organisms. Kidney disease never created a selection pressure to alter this effective danger response algorithm. Unique macrophage phenotypes contribute to all stages of these defense and repair programs; however, as the histomorphological abnormalities in CKD are complex, it remains technically difficult to dissect their presence in renal biopsies or their functional contribution to single diseases. Given the increasing knowledge about the plasticity of intrarenal dendritic cells, it is most likely that spatially and temporarily different microenvironments change the phenotype of macrophages as necessary. Therefore, a renal biopsy only displays a screenshot of dynamic processes not always providing an obvious clue to the underlying pathomechanisms. For the sake of a conceptual advance and a refined working hypothesis, we propose to classify macrophage phenotypes by their functional characteristics as proinflammatory, antiinflammatory, profibrotic, and fibrolytic macrophages. This classification does not entirely match with previous classifications, especially not with all aspects of the M1/M2 paradigm that is based on distinct in vitro culture conditions that do not sufficiently mirror in vivo environments. But the idea that the tissue microenvironments determine macrophage phenotypes allows us to intepret the present data in a different way and to design better experiments in the future.
Much more work remains to be done to more clearly define functionally important macrophage phenotypes in the different stages of each kidney disease (Figure 3) . However, we are confident that three conclusions will survive future discoveries: (1) blocking inflammatory macrophages protects from renal immunopathology, (2) the progression of renal fibrosis is associated with leukocyte infiltrates, which does not necessarily implicate inflammation, and (3) renal fibrosis develops rather as a result of insufficient epithelial and vascular healing. Therefore, controlling renal inflammation and promoting epithelial/vascular repair are probably the best ways to target renal fibrosis and to maintain renal function.
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